about
Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?Transcript levels of ten-eleven translocation type 1-3 in cervical cancer and non-cancerous cervical tissues.Replication study for the association of seven genome- GWAS-identified Loci with susceptibility to ovarian cancer in the Polish population.Assessment of pain and stress intensity among women with ovarian endometriomas versus teratomas.Overweight, obesity and female sexuality in perimenopause: a preliminary report.Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutationsGenomic mapping of pathways in endometrial adenocarcinoma and a gastrointestinal stromal tumor located in Meckel's diverticulumVitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish populationDNMT1, DNMT3A and DNMT3B gene variants in relation to ovarian cancer risk in the Polish populationUsefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumorsAn analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population.Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer.Senescent peritoneal mesothelium creates a niche for ovarian cancer metastases.Malignant presentation of uterine lymphangioleiomyomatosis.Recurrent endometrial hyperplasia as a presentation of estrogen-secreting thecoma - case report and minireview of the literature.Increased 17ß-hydroxysteroid dehydrogenase type 1 levels in primary cervical cancer.Advantages of implantation of acellular porcine-derived mesh in the treatment of human rectocele - Case report.Severe hyperandrogenemia in postmenopausal woman as a presentation of ovarian hyperthecosis. Case report and mini review of the literature.Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer.Disturbances of sleep continuity in women during the menopausal transition.Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy.The Proangiogenic Capabilities of Malignant Ascites Generated by Aggressive Ovarian Tumors.Malignant ascites determine the transmesothelial invasion of ovarian cancer cells.Serum arylesterase and paraoxonase activities in patients with ovarian tumors.Correlation between allopregnanolone levels and depressive symptoms during late menopausal transition and early postmenopause.External validation of the IOTA ADNEX model performed by two independent gynecologic centers.Ultrasonographic features and CA125 levels of hormonally active ovarian tumors.Role of osteopontin in differential diagnosis of ovarian tumors.Anaphylactic reaction to methylene blue dye after laparoscopic chromopertubation.Role of rs13117307 single nuclear polymorphism in the risk of uterine cervical cancer from Polish population and its impact on exocyst complex component 1 expression.Anti-ovarian antibodies in sera of patients with ovarian tumors.Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors.Comparison of diagnostic usefulness of predictive models in preliminary differentiation of adnexal masses.Artificial neural network computer prediction of ovarian malignancy in women with adnexal masses.Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.Hysteroscopy in fertility-sparing treatment in cases of atypical hyperplasia and early endometrial cancer – benefits and risksSalinomycin – a breakthrough in the treatment of ovarian cancer?The role of PD-1 – a programmed cell death receptor 1 – and its ligands in ovarian cancer immunotherapyVenous thromboembolism prophylaxis in cancer patients — guidelines focus on surgical patients
P50
Q33644633-B0FFFBE4-D454-43D9-BA12-3DE28B0034B6Q33684827-72FB4D01-6E84-4207-87DA-17DD90D703CDQ35578071-C70DDF3A-6EE5-4D42-80FD-C88B1D065B76Q35659786-A37B2CBF-0F32-4EEF-A173-8FAF0ACB8E8CQ35837038-B7DA168F-AE8B-4407-A3FF-8B09F15DD845Q36524235-C2AC8AD0-48E4-4185-A153-D97876DB4499Q36524629-F7E633B8-D5E0-4AC3-8105-F1503CD711C6Q36638586-F83536FF-0C84-42A2-B8D7-818CD5E9FEBCQ37046397-0BAAE74B-D5B3-46FB-AD54-E460270818D8Q37302215-AFFE91C9-879B-4982-A891-F452B5E40469Q37506531-80C7A21B-6F7F-4A83-BC53-DEBCB624FE92Q37581516-54667620-A9F2-49B7-8D0D-6F6F0CE6F139Q37603491-0CEAAE5E-8C64-4846-9A0E-0B1C7215BB77Q38621695-EB3BC997-CDA5-4974-B77D-08A9C08B9132Q38639148-1C2EADF3-0958-4B12-B701-B21514625ED8Q38866190-0884CCA5-4CFB-4B4E-809C-E58FCB8D9540Q39061419-78390573-5E0B-4684-8602-670726D1CE4CQ39366156-A4E197D5-E594-4E1E-A7BD-9C57BDA9ABD2Q39399146-6F2A9ECB-1A3C-4A65-AB18-C77180FFE9B7Q41479823-B8F369EF-929C-4D64-87AE-D5968D9D8AD4Q41615733-07C5AE8A-5563-402C-B747-D930E0A32F46Q42709077-A0407B72-0C07-41E1-976D-653FD05F9FBBQ46309697-9559BB37-D5B3-44A4-87F9-563D19F11812Q46798428-54735F69-66D4-4E24-9248-5320D9706C66Q47691179-7D737ECA-6726-4E65-8C34-CB1FEE02E92FQ47753522-F35790BF-E292-4CE8-B9CF-FDDB2C4478D3Q47765682-B77A3F4C-F4D4-4FBF-9C45-053CF4C4787EQ47960574-98A6FFFC-0BF5-4D63-811D-1CC8626EF5C0Q50495119-6893B9F6-28FF-4F1B-B347-3D17D711D4B7Q50537278-ED4902F6-DF24-45F4-A63B-528BFFBE007DQ50907447-0D236DBC-3369-45B8-A675-DF377FFB51C3Q51633169-FC88C2B1-753A-4640-9438-58C6A7C8B956Q51698863-114B0683-1A3A-4B56-B67A-EEC143560DCBQ51953628-638CA30F-8F47-4E46-A219-BB268A40C102Q51975467-FCF3B42A-8C46-4AA3-A446-C9543B1FEC32Q52858895-B79F6E80-05D8-4666-84DB-0DA11AC013B1Q58424211-114E1BDF-9E46-4B2A-91F5-C35B21C11D70Q58424224-2A781A1F-05A9-4098-91B2-7F3B0E71956CQ58424241-2150D69F-5F0B-4749-B73B-4C156864C14CQ58424248-EF6892CD-73DC-4E52-B981-386A684B2406
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Stefan Sajdak
@ast
Stefan Sajdak
@en
Stefan Sajdak
@es
Stefan Sajdak
@nl
Stefan Sajdak
@sl
type
label
Stefan Sajdak
@ast
Stefan Sajdak
@en
Stefan Sajdak
@es
Stefan Sajdak
@nl
Stefan Sajdak
@sl
prefLabel
Stefan Sajdak
@ast
Stefan Sajdak
@en
Stefan Sajdak
@es
Stefan Sajdak
@nl
Stefan Sajdak
@sl
P214
P106
P1153
7003842915
P21
P214
P31
P496
0000-0002-8641-4188
P735
P7859
viaf-163977505